First Comprehensive Amyloid Imaging Solution1

When evaluating for Alzheimer’s disease and other causes of cognitive decline

First Comprehensive Amyloid Imaging Solution1
 
Contact Us

Two major challenges for utilizing novel imaging biomarkers are limited access and low delivery reliability. Limited access results in the inability to offer new services to communities, limiting your ability to expand your clinical offerings and ultimately grow your business.

 

Likewise, low reliability results in patient dissatisfaction due to the need to reschedule imaging exams, which may damage the reputation between the imaging center and its referring physicians. Today, Siemens' PETNET Solutions operates the largest network of PET radiopharmaceutical manufacturing facilities for amyloid and other novel imaging biomarkers in the United States.

 

The combination of more complex and highly sensitive production and purification processes for next-generation PET imaging biomarkers demands the need for new production and purification techniques, as well as new manual and automated manufacturing steps. Addressing these manufacturing challenges, Siemens' PETNET solutions has standardized its equipment and training process across its entire production network to reduce the level of complexity in production. In addition, Siemens' PETNET Solutions has invested in redundant equipment for key processes to eliminate single points of failure. Finally, Siemens' PETNET Solutions employs dedicated staff and a fully-integrated operational support infrastructure for the global production of amyloid imaging biomarkers. As a result, Siemens' PETNET Solutions is able to offer imaging centers and hospitals a delivery reliability of up to 96 percent.
 

 

*Actual timing is based on local regulatory approvals at each site.